By Mariam Sunny and Michael Erman Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 24.4% in the morning session after the company reported ...

Novavax Inc. NVAX shares are up on Thursday following the company’s announcement of its fourth-quarter and full-year 2025 financial results. Earnings Novavax reported fourth-quarter earnings of 11 ...

Novavax’s modeled fair value has been reset to US$13.78 from US$13.11, a small move that still matters if you are tracking how assumptions are shifting. Behind that change, recent Street research ...

Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...

Novavax Inc. shares are down on Friday, possibly on profit-taking after the stock rallied on Thursday following the company's announcement of its fourth-quarter and full-year 2025 financial results.

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...

Shares of Novavax Inc. NVAX slipped 6.13% to $9.49 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.02% to ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 2:30 PM ESTCompany ParticipantsJohn Jacobs - President, CEO ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

The MarketWatch News Department was not involved in the creation of this content. -- Non-exclusive license allows for development by Pfizer to utilize Matrix-M(R) for up to two disease areas with its ...